Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
78.13 USD | -0.24% | +12.32% | +9.09% |
Jul. 09 | RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating | MT |
Jul. 01 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.09% | 8.25B | |
+8.07% | 101B | |
+8.29% | 42.63B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B | |
-55.52% | 8.98B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Transcript : Intra-Cellular Therapies, Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-12-2021 06